PLX — Protalix Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $92.78m
- $89.39m
- $65.49m
- 21
- 75
- 51
- 47
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -18.3 | -6.52 | -27.6 | -14.9 | 8.31 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 4.14 | 6.25 | 6.28 | 0.856 | 2.81 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -6.83 | -27.1 | 9.9 | -12 | -10.5 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -19.4 | -26.1 | -10.3 | -25 | -1.32 |
Capital Expenditures | -0.627 | -0.655 | -1.46 | -0.628 | -1.15 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -0.256 | -19.3 | 20.4 | -4.41 | -15.6 |
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.883 | -20 | 18.9 | -5.04 | -16.7 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0 | 46.5 | 12.1 | 8.24 | 24.7 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -20 | 0.473 | 20.7 | -21.9 | 6.52 |